June 4, 2021

Prevention and Attenuation of COVID-19 by BNT162b2 and mRNA-1273 Vaccines

Category: Article Summary

Topic: Vaccines and Immunity

Keywords (Tags): immunity, vaccines

• [Pre-print, not peer-reviewed] A prospective cohort study (N=3,975) of healthcare personnel and other frontline workers estimated the real-world effectiveness of Pfizer-BioNTech and Moderna COVID-19 vaccines and found that the adjusted effectiveness of full vaccination was 92% (95% CI 76-97%) and effectiveness of partial vaccination was 81% (95% CI 64-90%). Additionally, among partially or fully vaccinated participants who became infected SARS-CoV-2, mean viral RNA load was 40% lower, the risk of self-reported febrile COVID-19 was 58% lower, and vaccinated individuals experienced 2.3 fewer days spent sick in bed compared to unvaccinated participants with SARS-CoV-2 infection. The authors conclude that these results indicate that mRNA vaccines are highly effective among working-age adults in preventing SARS-CoV-2 infection and decreasing viral load, symptoms, and illness duration.

Thompson et al. (June 3, 2021). Prevention and Attenuation of COVID-19 by BNT162b2 and mRNA-1273 Vaccines. Pre-print downloaded Jun 4 from https://doi.org/10.1101/2021.06.01.21257987